Publications by authors named "Arturo Cadena-Fernandez"
Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
Eur J Neurol
November 2022
Article Synopsis
- * The study found 97 cases of GBS with an overall incidence of 1.19 per million doses, noting higher risks associated with specific vaccines like Ad26.COV2-S and BNT162b2.
- * Despite the low incidence, GBS onset typically occurred about 10 days post-vaccination, with a notable proportion of patients requiring significant medical intervention and experiencing severe disability outcomes.
Objectives: The antiphospholipid syndrome (APS) is an autoimmune disease associated with thrombotic and non-thrombotic neurologic manifestations. APS is classified as primary (PAPS) or secondary (SAPS) when it co-exists with another autoimmune disease. We aim to describe the spectrum of acute cerebrovascular disease among patients with APS, their differences between stroke subtypes, and long-term functional outcomes.
View Article and Find Full Text PDFmRNA-based COVID-19 vaccines are effective; however, persistent vaccine hesitancy is partly due to a misperception of their potential adverse events. Non-specific sensory symptoms (NSSS) following immunization are thought to be mediated by stress-related responses. In this case-control study, we evaluated NSSS from a cohort of 7,812,845 BNT162b2 first-dose recipients, of whom 10,929 reported an adverse event following immunization (AEFI).
View Article and Find Full Text PDFBackground: Coronavirus disease 2019 (COVID-19) is a systemic disease that can rapidly progress into acute respiratory failure and death. Timely identification of these patients is crucial for a proper administration of health-care resources.
Objective: To develop a predictive score that estimates the risk of invasive mechanical ventilation (IMV) among patients with COVID-19.
Objective: Cyclophosphamide (CYC) is an alkylating agent with immunosuppressive effect by inhibiting DNA synthesis and producing apoptosis used in many autoimmune diseases, including multiple sclerosis (MS). Here, we analyze the efficacy of CYC treatment in relapsing-remitting (RRMS) and active secondary progressive MS (SPMS) in our center with a monthly scheme.
Methods: Patients with MS treated with CYC and a follow up of at least 36 months were eligible for inclusion.